PRECISIS GmbH
Precisis AG: Scientific launch of Precisis’ CobraLeaf(R)
Heidelberg – Precisis AG have now presented their newest development, the CobraLeaf(R) multi leaf collimator for Radiotherapy, scientifically in the emerging markets. With the expectations highly excelled, both Precisis AG and Radiation oncologists express their excitement about the soon market launch. Supported by the first scientific presentation at the annual AMPICON conference (Conference of the Association of Medical Physicists in India) in Mangalore, India, Precisis AG has now widely approached the target market in the emerging countries. The CobraLeaf(R) concept, which connects modern treatments methods in radiotherapy with high cost-efficiency and maximum reliability for use in low- and middle income countries, was stirring expectations since its first publication in September 2012. Dr. Lokesh Viswanath M.D Professor Radiation Oncology at the Kidwai Memorial Institute of Oncology in Bangalore, India explains that 'there is a real and urgent need to demonstrate to the world, that a cost-effective 3D Conformal Radiotherapy (CRT), which is the basic minimum standard of care in Radiation Therapy can be given on a Telecobalt Machine with a MLC. A simple low cost accessory like this will benefit many patients throughout the world, especially in many developing nations. Hence, we deeply appreciate the effort by Precisis AG and DKFZ to bring this to the market.' The CobraLeaf(R) collimator, developed in close cooperation with the German Cancer Research Center (DKFZ) in Heidelberg and the support of Best Theratronics, Canada, is a mechanical beam limiting device which now makes it possible, for the first time, to precisely customize the beam to the tumor shape in cobalt machines. 'The exclusively positive feedback from first-hand users boosts our conviction that this product is definitely going to change the treatment for cancer patients throughout the world. This team of scientists, experienced engineers and designers has done a great job in the last few months to make this happen', says Stefan Ueltzhöffer, head of Innovation Management at Precisis AG.
During ongoing improvements and testing, several reference centers for immediate and broad distribution of the new method are beeing selected and will be equipped beginning of 2013. About Precisis AG
Precisis AG perceives itself as an innovative solution provider for stereotactic neurosurgery and radiation therapy. Alongside the enhancement of precision software systems that are already established in the market such as PraezisPlus(R) and Virtuos(R), the Heidelberg-based medical technology provider also works to advance the use of cranial brachytherapy, precision neurosurgery and special radiotherapy techniques. Its international team of ten employees is led by company president Dr. Angela Liedler, an experienced healthcare marketing and enterprise professional. About CobraLeaf(R) The CobraLeaf(R) collimator, developed in close cooperation with the German Cancer Research Center (DKFZ) in Heidelberg, is a mechanical beam limiting device which now makes it possible, for the first time, to precisely customize the beam to the tumor shape in cobalt machines.
In contrast to Linear accelorators (LINAC), Cobalt machines do not rely on stable power supply and do tolerate voltage fluctuations. With CobRaLeaf(R), their beam can now be customized to the shape of the tumor. This improves the impact on the cancerous tissue while sparing the surrounding healthy tissue. This high precision treatment technique in radiotherapy was exclusive to wealthy healthcare infrastructures, but can now be offered to a much wider range of patients. About DKFZ The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 2,500 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg where promising approaches from cancer research are translated into the clinic. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. The center is a member of the Helmholtz Association of National Research Centers. Ninety percent of its funding comes from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg. End of Media Release The picture belonging to this press release can be found here: http://newsfeed2.equitystory.com/precisis/197279.html Caption: Erste wissenschaftliche Präsentation des Precisis CobraLeaf(R) Issuer: Precisis AG Key word(s): Research/Technology 18.12.2012 Dissemination of a Press Release, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
197279 18.12.2012 |